A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure.

JACC Basic Transl Sci · 2016 · PMC6113538 · PMID 30167542

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Additionally, at the 90-day time point there was a nonsignificant trend toward a reduction in LVESV, especially at the higher doses (-23.2 ml compared with baseline).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.